IL18 and complement in collagen induced arthritis
IL18 and complement in collagen induced arthritis
批准号:
6227682
负责人:
WILLIAM P AREND
金额:
$25.04万
依托单位国家:
美国
项目类别:
财政年份:
1999
资助国家:
美国
项目状态:
已结题
起止时间:
1999-09-28 至 2003-08-31
中文摘要
点击翻译按钮获取中文摘要
英文摘要
The long-term objectives of this project are to determine the roles of IL- 18 and the complement system in the induction of IL-1 and TNFalpha in collagen-induced arthritis (CIA) in mice and in rheumatoid synovial cells. IL-1 and TNFalpha are important mediators of tissue damage in rheumatoid arthritis (RA) and in CIA through stimulation of production of metalloproteinases in synovial fibroblasts and chondrocytes. The mechanisms of excess production of these cytokines in RA or CIA are probably multiple and largely unknown; IL-18 and the complement system are two potential inducers of IL1 and TNFalpha. The hypothesis to be examined in these studies is that inhibition of IL-18 with the specific IL-18 binding protein (IL-18BP), and of complement with the murine inhibitor, Crry, will attenuate the onset or ameliorate the course of CIA. This question will be addressed through three specific aims: 1) to examine the effects on CIA in mice of prevention of receptor binding of IL-18 with soluble IL-18BP; 2) to examine the effects of CIA in mice of blocking both the complement system and IL-18; and 3) to examine the relationship between production of IL-18, TNFalpha, and IL- 1beta in rheumatoid synovial tissue and cells. These experiments will utilize the administration of recombinant IL-18BP, the creation of mice transgenic for either, or both, proteins, and studies on isolated rheumatoid synovium tissue and cells. These studies are relevant to RA where IL-1 and TNFalpha are key mediators leading to inflammation and tissue destruction. The complement system and IL-18 may be important inducers of IL-1 and TNFalpha. These studies are further relevant to other autoimmune and inflammatory diseases where inhibition of injurious mechanisms at the proximal levels of complement and IL-18 may be efficacious. This research project will contribute towards the broad objective of the Autoimmunity Centers of Excellence program to study the mechanisms of new interventional approaches in both animal models of disease and in human disease.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
IL18 and complement in collagen induced arthritis
-
批准号:6354597
-
项目类别:
-
资助金额:$25.04万
-
财政年份:2000
-
负责人:WILLIAM P AREND
-
依托单位:
NOT STATED
-
批准号:3433791
-
项目类别:
-
资助金额:$1.0万
-
财政年份:1993
-
负责人:WILLIAM P AREND
-
依托单位:
REGULATION OF IL-1BETA & IL-1 INHIBITOR GENE EXPRESSION
-
批准号:3160192
-
项目类别:
-
资助金额:$17.82万
-
财政年份:1990
-
负责人:WILLIAM P AREND
-
依托单位:
ROLE OF INTERLEUKIN-1 INHIBITOR--INFLAMMATORY SYNOVITIS
-
批准号:3160420
-
项目类别:
-
资助金额:$14.65万
-
财政年份:1990
-
负责人:WILLIAM P AREND
-
依托单位:
IL1 RECEPTOR ANTAGONIST INTRACELLULAR VARIANTS
-
批准号:6171246
-
项目类别:
-
资助金额:$26.76万
-
财政年份:1990
-
负责人:WILLIAM P AREND
-
依托单位:
IL1 RECEPTOR ANTAGONIST--INTRACELLULAR VARIANTS
-
批准号:2683284
-
项目类别:
-
资助金额:$22.86万
-
财政年份:1990
-
负责人:WILLIAM P AREND
-
依托单位:
IL1 RECEPTOR ANTAGONIST INTRACELLULAR VARIANTS
-
批准号:2849915
-
项目类别:
-
资助金额:$26.24万
-
财政年份:1990
-
负责人:WILLIAM P AREND
-
依托单位:
IL1 RECEPTOR ANTAGONIST--INTRACELLULAR VARIANTS
-
批准号:2079857
-
项目类别:
-
资助金额:$20.54万
-
财政年份:1990
-
负责人:WILLIAM P AREND
-
依托单位:
IL1 RECEPTOR ANTAGONIST--INTRACELLULAR VARIANTS
-
批准号:2079858
-
项目类别:
-
资助金额:$21.09万
-
财政年份:1990
-
负责人:WILLIAM P AREND
-
依托单位:
REGULATION OF IL-1BETA & IL-1 INHIBITOR GENE EXPRESSION
-
批准号:3160193
-
项目类别:
-
资助金额:$21.17万
-
财政年份:1990
-
负责人:WILLIAM P AREND
-
依托单位:
IL1 RECEPTOR ANTAGONIST--INTRACELLULAR VARIANTS
-
批准号:2390505
-
项目类别:
-
资助金额:$22.24万
-
财政年份:1990
-
负责人:WILLIAM P AREND
-
依托单位:
ROLE OF INTERLEUKIN-1 INHIBITOR--INFLAMMATORY SYNOVITIS
-
批准号:3160417
-
项目类别:
-
资助金额:$11.54万
-
财政年份:1990
-
负责人:WILLIAM P AREND
-
依托单位:
IL1 RECEPTOR ANTAGONIST INTRACELLULAR VARIANTS
-
批准号:6632525
-
项目类别:
-
资助金额:$28.42万
-
财政年份:1990
-
负责人:WILLIAM P AREND
-
依托单位:
ROLE OF INTERLEUKIN-1 INHIBITOR--INFLAMMATORY SYNOVITIS
-
批准号:3160419
-
项目类别:
-
资助金额:$12.0万
-
财政年份:1990
-
负责人:WILLIAM P AREND
-
依托单位:
IL1 RECEPTOR ANTAGONIST--INTRACELLULAR VARIANTS
-
批准号:2079859
-
项目类别:
-
资助金额:$21.66万
-
财政年份:1990
-
负责人:WILLIAM P AREND
-
依托单位:
IL1 RECEPTOR ANTAGONIST INTRACELLULAR VARIANTS
-
批准号:6374919
-
项目类别:
-
资助金额:$27.3万
-
财政年份:1990
-
负责人:WILLIAM P AREND
-
依托单位:
REGULATION OF IL-1BETA & IL-1 INHIBITOR GENE EXPRESSION
-
批准号:3160190
-
项目类别:
-
资助金额:$17.82万
-
财政年份:1990
-
负责人:WILLIAM P AREND
-
依托单位:
IL1 RECEPTOR ANTAGONIST INTRACELLULAR VARIANTS
-
批准号:6511699
-
项目类别:
-
资助金额:$27.85万
-
财政年份:1990
-
负责人:WILLIAM P AREND
-
依托单位:
RESEARCH TRAINING IN RHEUMATOLOGY
-
批准号:2909766
-
项目类别:
-
资助金额:$11.4万
-
财政年份:1986
-
负责人:WILLIAM P AREND
-
依托单位:
RESEARCH TRAINING IN RHEUMATOLOGY
-
批准号:3532174
-
项目类别:
-
资助金额:$6.99万
-
财政年份:1986
-
负责人:WILLIAM P AREND
-
依托单位:
国内基金
海外基金
登录
查看更多内容
骨胶原(Bio-Oss Collagen)联合龈下喷砂+骨皮质切开术治疗
根分叉病变的临床疗效研究
-
批准号:2024JJ9542
-
项目类别:省市级项目
-
资助金额:--
-
批准年份:2024
-
负责人:潘涛华
-
依托单位:
靶向A2BR/CollagenⅠ通路抑制循环肿瘤细胞团形成阻断肺癌转移的机制研究
-
批准号:82303467
-
项目类别:青年科学基金项目
-
资助金额:30万元
-
批准年份:2023
-
负责人:李青芳
-
依托单位:
HRD1通过调控自噬介导肺纤维化肌成纤维细胞collagen-Ⅰ高分泌的机制研究
-
批准号:82200080
-
项目类别:青年科学基金项目
-
资助金额:30万元
-
批准年份:2022
-
负责人:刘媛媛
-
依托单位:
Collagen VI 通过线粒体代谢/巨噬细胞调节机制调控CINP 的发生发展
-
批准号:2021JJ41060
-
项目类别:省市级项目
-
资助金额:--
-
批准年份:2021
-
负责人:朱小燕
-
依托单位:
基于Collagen/GPVI通路调控肿瘤基质屏障/凝血屏障增强anti-PD-1治疗乳腺癌药效及机制研究
-
批准号:82102917
-
项目类别:青年科学基金项目(C类)
-
资助金额:30.0万元
-
批准年份:2021
-
负责人:朱运
-
依托单位:
肝星型细胞分泌 collagen I 激活盘状结构域受体DDR1-STAT3信号轴促进葡萄膜黑色素瘤肝转移的研究
-
批准号:82003797
-
项目类别:青年科学基金项目
-
资助金额:16.0万元
-
批准年份:2020
-
负责人:戴伟
-
依托单位:
基于皮肤类器官模型探究TGFβ-Collagen-ROCK分子模块调控皮肤及其附属器官再生的机制
-
批准号:82003384
-
项目类别:青年科学基金项目
-
资助金额:24.0万元
-
批准年份:2020
-
负责人:雷明星
-
依托单位:
四跨膜蛋白Tetraspanin 1结合Collagen I在特发性肺纤维化发病中的分子机制研究
-
批准号:82070061
-
项目类别:面上项目
-
资助金额:55.0万元
-
批准年份:2020
-
负责人:刘刚
-
依托单位:
MGF-Notch/CollagenⅤ/CalcR-MSC:推拿增强骨骼肌重塑的新机制
-
批准号:81904318
-
项目类别:青年科学基金项目
-
资助金额:21.0万元
-
批准年份:2019
-
负责人:丁海丽
-
依托单位:
CDX2/MMP1/Collagen-I正反馈通路介导的细胞外基质重构在结直肠癌侵袭转移中的作用机制研究
-
批准号:81972720
-
项目类别:面上项目
-
资助金额:55.0万元
-
批准年份:2019
-
负责人:孙学军
-
依托单位: